Эпидемиология первичного гиперпаратиреоза в России (первые результаты по базе данных ФГУ ЭНЦ)
https://doi.org/10.14341/probl20115733-10
Аннотация
Список литературы
1. Голохвастов Н.Н., Эммануэль В.Л., Рыбакова Г.В., Мягков Л.В. Скрининг кальция крови стационарных больных для выявления первичного гиперпаратиреоза. Современные аспекты хирургической эндокринологии. Саранск 1997;82-85.
2. Marx S.J. Multiple endocrine neoplasia type 1. In: The metabolic and molecular bases of inherited disease, 8th ed. Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle. New York 2001;943-966.
3. Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17:Suppl 2:N18-N23.
4. Flynn R.W., Macdonald T.M., Jung R.T. et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006;91:2159-2164.
5. Morris A.D., Boyle D.I., MacAlpine R. et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. Br Med J 1997;315:524-528.
6. Котова И.В., Титова Н.В. Бессимптомный и нормокальциемический первичный гиперпаратиреоз (обзор литературы и собственные наблюдения). Пробл эндокринол и патол (Украина) 2003;1:8-12.
7. Печерская Г.А., Ишенин Ю.М. Диагностические аспекты первичного гиперпаратиреоза. Казан мед журн 2000;3:226-227.
8. Bilezikian J.P., Potts J.T., Fuleihan G.E. et al. Summary statement from a workshop on asymptomatic primary hyperthyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-5361.
9. NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Int Med 1991;114:7:593-597.
10. Jorde R., Bonaa K.H., Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000;53:1164-1169.
11. Wermers R.A., Atkinson E.J., Achenbach S.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:1:171-177.
12. Yu N., Donnan P.T., Murphy M.J., Leese G.P. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf) 2009;71:4:485-493.
13. Blichert-Toft M., Mollerup C.L., Feldt-Rasmussen U.F. et al. Primary hyperparathyroidism. An underdiagnosed disease in Denmark. Ugeskr Laeger 1993;155:765-769.
14. The Mattson Jack Group. Epidemiology of Primary Hyperparathyroidism in Europe - report commissioned by Amgen. Ref Type: Report 2003.
15. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 2005;11:1:49-54.
16. Richert L., Trombetti A., Herrmann F.R. et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swiss Med Wkly 2009;139:27-28:400-404.
17. Weber T., Keller M., Hense I. et al. Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism. World J Surg 2007;31:1202-1209.
18. Brandi M.L., Gagel R.F., Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:12:5658-5671.
19. Uchino S., Noguchi S., Sato M. et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000;60:5553-5557.
20. Melton L.J. Mayo Clinic, Rochester, Minnesota, USA. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Int Med 1997;126:6:433-440.
21. Vestergaard P., Mosekilde L. Incidence of primary hyperparathyroidism, frequency of surgical interventions and ortality based on the data from the National Patient Registry. Ugeskr Laeger 2004;166:41-45.
22. De Geronimo S., Romagnoli E., Diacinti D.et al. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol 2006;155:3:415-420.
23. Asgharian B., Turner M.L., Gibril F. et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 2004;89:11:5328-5336.
24. Geerdink E.A., Van der Luijt R.B., Lips C.J. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 2003;149:6:577-582.
25. Ikeo Y., Sakurai A., Hashizume K. Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies. Jpn J Cancer Res 1999;90:10:1088-1095.
26. Piecha G., Chudek J., Wiecek A. Multiple Endocrine Neoplasia type 1. Eur J Int Med 2008;19:2:99-103.
27. Eller-Vainicher C., Chiodini I., Battista C. et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 2009;24:8:1404-1410.
28. Trump D., Farren B., Wooding C. et al. Clinical studies of multiple endocrine neoplasia type 1 (MENI). Q J Med 1996;89:653-669.
29. Makras P., Papapoulos S.E. Medical treatment of hypercalcaemia Hormones (Athens). 2009;8:2:83-95.
30. Palmér M., Jakobsson S., Akerström G., Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Inv 1988;18:1:39-46.
Рецензия
Для цитирования:
, , , , , Эпидемиология первичного гиперпаратиреоза в России (первые результаты по базе данных ФГУ ЭНЦ). Проблемы Эндокринологии. 2011;57(3):3-10. https://doi.org/10.14341/probl20115733-10
For citation:
Dedov I.I., Mokrysheva N.G., Mirnaia S.S., Rostomian L.G., Pigarova E.A., Rozhinskaia L.I. Epidemiology of primary hyperparathyroidism in Russia (the first results from the database of Federal state institution «Endocrinological Research Centre»). Problems of Endocrinology. 2011;57(3):3-10. (In Russ.) https://doi.org/10.14341/probl20115733-10

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).